92 related articles for article (PubMed ID: 22924699)
1. DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia.
Leo E; Mancini M; Aluigi M; Castagnetti F; Martinelli G; Barbieri E; Santucci MA
Br J Haematol; 2012 Nov; 159(3):373-6. PubMed ID: 22924699
[No Abstract] [Full Text] [Related]
2. DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia.
Leo E; Mancini M; Castagnetti F; Gugliotta G; Santucci MA; Martinelli G
J Cell Biochem; 2015 Apr; 116(4):589-97. PubMed ID: 25389112
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
4. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.
Bozkurt S; Özkan T; Özmen F; Baran Y; Sunguroğlu A; Kansu E
Hematology; 2013 Jul; 18(4):217-23. PubMed ID: 23394612
[TBL] [Abstract][Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
6. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.
Katagiri S; Umezu T; Ohyashiki JH; Ohyashiki K
Br J Haematol; 2013 Jan; 160(2):269-71. PubMed ID: 23116058
[No Abstract] [Full Text] [Related]
7. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
[TBL] [Abstract][Full Text] [Related]
10. Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein.
Brown S; Hutchinson CV; Aspinall-O'Dea M; Whetton AD; Johnson SM; Rees-Unwin K; Burthem J
Eur J Haematol; 2014 Aug; 93(2):96-102. PubMed ID: 24617663
[TBL] [Abstract][Full Text] [Related]
11. UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib.
Synowiec E; Hoser G; Wojcik K; Pawlowska E; Skorski T; Błasiak J
Int J Mol Sci; 2015 Aug; 16(8):18111-28. PubMed ID: 26251899
[TBL] [Abstract][Full Text] [Related]
12. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
13. In cancer drug resistance, germline matters too.
Cheng EH; Sawyers CL
Nat Med; 2012 Apr; 18(4):494-6. PubMed ID: 22481406
[No Abstract] [Full Text] [Related]
14. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
15. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Gniot M; Wasilewska EM; Lewandowski K
Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
[No Abstract] [Full Text] [Related]
16. BCR-ABL1 in leukemia: disguise master outplays riding shotgun.
Rana A; Ali GM; Ali S; Khan A; Mansoor S; Malik S; Farooqi AA
J Cancer Res Ther; 2013; 9(1):6-10. PubMed ID: 23575066
[TBL] [Abstract][Full Text] [Related]
17. Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.
Liu Y; Zheng W; Song Y; Ma W; Yin H
PLoS One; 2013; 8(7):e68442. PubMed ID: 23894305
[TBL] [Abstract][Full Text] [Related]
18. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
19. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
Nadarajan VS; Ang CH; Bee PC
Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
[TBL] [Abstract][Full Text] [Related]
20. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]